Amino Science Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration. Full disclaimer.
🔥 FREE SHIPPING ON ORDERS OVER $250 🔥
Research Peptide
For Research Use Only: This product is not intended for human or veterinary use. Supply is limited strictly to laboratory research, analytical assay development, or investigative procedures only.
Buy 1 Get 1 FREE!
On select sizes — each card shows the vials you get and what you pay.
Fast shipping
Same-day dispatch
Third-party tested
U.S. accredited labs
99%+ purity
HPLC verified
2x
DUAL AGONIST
GLP-1 and GIP receptors
22.5%
WEIGHT LOSS
In Phase 3 SURMOUNT-1 trial
2022
FDA APPROVED
As Mounjaro for T2D
1000+
PUBLICATIONS
Tirzepatide research papers
39AA
SEQUENCE
Modified GIP analogue with GLP-1 activity
Free shipping
on orders over $150
Quality guarantee
99%+ purity verified
Secure checkout
256-bit SSL encryption
Research
GLP-2 TIRZ is supplied as a combined lyophilized research preparation pairing a GLP-2 (glucagon-like peptide-2) research peptide with tirzepatide, a synthetic dual incretin-class peptide that engages both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor pathways. The listed molecular formula, C225H348N48O68 (average mass approximately 4814 g/mol), corresponds to the tirzepatide component and reflects the fatty-acid-modified backbone characteristic of long-acting incretin-mimetic research peptides. This material is offered strictly For Research Use Only and is not intended for human or veterinary use; supply is limited to laboratory research, analytical assay development, and investigative procedures. It is not a drug, supplement, or food.
The two peptide classes represented in this preparation have each been the subject of separate bodies of preclinical and in-vitro literature. GLP-2 has been studied in cell-culture and animal models for its role in intestinal epithelial receptor signaling mediated through the GLP-2 receptor. Tirzepatide has been characterized in receptor-binding, cyclic-AMP signaling, and rodent model studies as a unimolecular agonist active at both GIP and GLP-1 receptors. Combining the two in a single research preparation is of interest to investigators studying gut-peptide receptor crosstalk, comparative incretin signaling, and multi-receptor pharmacology in controlled in-vitro systems. All such work to date is preliminary, ongoing, and mechanistic in nature; this content is educational and does not constitute medical advice, and no human or clinical conclusions should be drawn from it.
Each research lot is characterized to a purity specification of at least 99 percent and released against a certificate of analysis (COA). Identity and purity are established using orthogonal analytical methods appropriate to synthetic peptides of this size.
For Research Use Only. Not for human or veterinary use. Handle only under appropriate laboratory conditions by qualified personnel. The information here is provided for analytical and educational reference and makes no therapeutic claims.
It is a combined lyophilized peptide research preparation containing a GLP-2 research peptide together with tirzepatide, a dual GIP/GLP-1 receptor agonist peptide. The listed formula (C225H348N48O68, ~4814 g/mol) corresponds to the tirzepatide component. It is supplied strictly for in-vitro and preclinical laboratory research, not for any human or veterinary application.
Purity of at least 99 percent is assessed by reversed-phase HPLC, and molecular identity is confirmed by mass spectrometry (ESI-MS or MALDI-TOF) against the theoretical mass. Each lot ships with a certificate of analysis documenting chromatographic purity, mass-spec identity, and appearance, referenced to catalog code DA-78491.
In preclinical studies, tirzepatide has been characterized as an agonist at both the GIP and GLP-1 receptors, while the GLP-2 component acts at the distinct GLP-2 receptor. Researchers use combined preparations to study incretin and gut-peptide receptor signaling and crosstalk in controlled cell and animal models. This is mechanistic research only and implies no health outcome.
The content provided here reflects preclinical, in-vitro, and analytical research contexts only. This material is not a drug and is not intended for human or animal administration. No human dosing, efficacy, or safety claims are made, and any such interpretation would be outside the scope of this research-use product.
It should be handled only by trained personnel using standard laboratory practice for lyophilized synthetic peptides, with reconstitution and aliquoting performed under appropriate controlled conditions. Refer to the storage guidance shown elsewhere on the product page and to the lot COA for material-specific details.
This product is sold strictly for in-vitro research and laboratory use only. It is not intended for human or animal consumption, diagnostic purposes, or therapeutic application.
By purchasing this product, you confirm that you are a qualified researcher operating within an appropriate laboratory environment and will use this compound in accordance with all applicable local, state, and federal regulations.
Amino Science Labs assumes no liability for misuse of this product outside of its intended research application.
For blended peptide research preparations, the primary published formula typically reflects the dominant or best-characterized component, here tirzepatide (C225H348N48O68). Each individual peptide retains its own molecular identity in the mixture; mass spectrometry on the COA confirms the expected masses present in the preparation.
